Ultra-Long Acting Insulin Glargine

Lead Participant: Arecor Limited


The aim of the project is to use innovative formulation technology to develop a proof-ofconcept
for insulin product with a consistent, ultra-long release profile. Formulations will first
be validated with the use of an in vitro model before demonstrating the ultra-long release
profile in a relevant animal model. Arecor is a biotherapeutic formulation company with a
technology that has the ability to elongate the time action profile of insulin whilst maintaining
a product stability profile suitable for commercialisation. The duration of action for currently
marketed products is less than 24 hours in at least a third of patients, which increases the risk
of severe life-threatening hypoglycaemic episodes. A consistent, elongated release profile will
offer reduced hypoglycaemic risk, whilst in turn improving dose flexibility resulting in
improved patient compliance, health benefits and savings for the healthcare provider.

Lead Participant

Project Cost

Grant Offer

Arecor Limited, Cambridge, United Kingdom £99,429 £ 59,657


10 25 50